Eyenovia, Inc. (NASDAQ:EYEN) Sees Significant Increase in Short Interest

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 249,400 shares, an increase of 346.2% from the January 31st total of 55,900 shares. Based on an average daily volume of 366,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 12.1% of the company’s stock are short sold.

Eyenovia Trading Down 2.3 %

Shares of EYEN stock opened at $1.72 on Friday. The stock has a fifty day simple moving average of $5.01 and a two-hundred day simple moving average of $23.58. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. Eyenovia has a 52-week low of $1.43 and a 52-week high of $205.60. The firm has a market capitalization of $2.40 million, a PE ratio of -0.03 and a beta of 1.25.

Hedge Funds Weigh In On Eyenovia

An institutional investor recently raised its position in Eyenovia stock. Nations Financial Group Inc. IA ADV grew its holdings in shares of Eyenovia, Inc. (NASDAQ:EYEN) by 78.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,900 shares of the company’s stock after buying an additional 40,000 shares during the quarter. Nations Financial Group Inc. IA ADV owned 0.14% of Eyenovia worth $47,000 at the end of the most recent reporting period. Institutional investors own 25.84% of the company’s stock.

Wall Street Analyst Weigh In

EYEN has been the subject of several analyst reports. LADENBURG THALM/SH SH restated a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th. HC Wainwright restated a “neutral” rating and set a $2.00 price target on shares of Eyenovia in a research note on Thursday, February 6th. Finally, Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.